February 2010

Karus develops new family of HDAC-6 selective inhibitors

(PDF 455KB)

September 2009

Karus Therapeutics and Queen Mary, University of London announce PI3 Kinase Collaboration

(PDF 84KB)

August 2009

Karus CSO to present at three industry conferences

(PDF 66KB)

June 2009

Organ Transplant Rejection Collaboration with University Hospital Birmingham

(PDF 70KB)

May 2009

KTP Award with King's College

(PDF 62KB)

April 2009

Karus announces second closing of investment

(PDF 59KB)

January 2009

Karus CEO talks to Pharma TV

January 2009

Karus Therapeutics secures investment

(PDF 64KB)

October 2008

Karus CSO presents at major industry conference

(PDF 64KB)

April 2008

Ann Hacker joins Karus Board

(PDF 65KB)

January 2008

Karus appoints Stephen Shuttleworth as Chief Scientific Officer

(PDF 65KB)

October 2007

Karus Scientist presents at key industry conferences

(PDF 66KB)

October 2007

Karus signs co-development agreement with EOS

(PDF 63KB)

July 2007

Karus raises £0.82 investment

(PDF 65KB)

October 2006

Drummond Paris named as Chairman of Karus Therapeutics

(PDF 86KB)

May 2006

Karus Therapeutics appoints Simon Kerry as CEO

(PDF 60KB)

December 2005

Collaboration with Sareum Holdings

(PDF 73KB)

July 2005

Cancer and heart disease drug discovery company is latest spin-out from the University of Southampton

(PDF 56KB)

Ganesan et al

The bicyclic depsipeptide family of histone deacetylase inhibitors in: Chemical Biology: From Small Molecules to Systems Biology and Drug Design; Wiley-VCH 2007

Packham et al

Characterisation of the in vitro activity of the depsipeptide histone deacetylase inhibitor spiruchostatin A ; Biochem Pharmacol 2008

(PDF 1,104KB)

Yurek-George, et al

The first biologically active synthetic analogues of FK228, the depsipeptide histone deacetylase inhibitor; J Med Chem; 2007

(PDF 126KB)

Yurek-George, et al

Total synthesis of Spiruchostatin A, a potent histone deacetylase inhibitor; J Am Chem Soc; 2004

(PDF 64KB)

Davidson, et al

The transcriptional coactivator p300 plays a critical role in the hypertrophic and protective pathways induced by phenylephrine in cardiac cells…; Chem Biochem; 2005

(PDF 238KB)